Fundraising FoxCrestecbio
1 known investors
Find your way into Crestecbio
Sign up to see every warm intro you have to Crestecbio
- Paths you didn't know you had: your email and LinkedIn already hold routes to the Crestecbio team. We find them
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes you can't see from your own inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
Crestec Bio develops CTB211, a redox nanoparticle (polymer micelle carrying the TEMPO nitroxide radical scavenger) originally researched at the University of Tsukuba, designed to scavenge reactive oxygen species and protect neural cells. It is being developed as a therapeutic to reduce reperfusion injury after thrombectomy in ischemic stroke patients, with a focus on brain and organ disorders.
Investors · 1
Frequently asked questions
- What does Crestecbio do?
- Crestec Bio develops CTB211, a redox nanoparticle (polymer micelle carrying the TEMPO nitroxide radical scavenger) originally researched at the University of Tsukuba, designed to scavenge reactive oxygen species and protect neural cells. It is being developed as a therapeutic to reduce reperfusion injury after thrombectomy in ischemic stroke patients, with a focus on brain and organ disorders.
- Who are Crestecbio's investors?
- Crestecbio's investors include UntroD Capital.